CPT 0616U TruD MDS Reimbursement & Policy | OpenPayer

Summary & Overview

CPT 0616U: TruD MDS Alzheimer's & MCI Methylation Risk Assay

CPT code 0616U designates a Proprietary Laboratory Analyses (PLA) assay — the TruD MDS Alzheimer's & MCI test from TruDiagnostic™ Inc. — that assesses DNA methylation at more than 30,000 CpG sites in whole blood and applies an algorithm to report a positive or negative dementia-related risk. As a PLA code, 0616U is specific to a single manufacturer’s assay and signals a precision-medicine, laboratory-developed test entering the clinical and payer landscape. Nationally, PLA codes matter because they identify proprietary tests that can influence coverage policies, prior authorization workflows, and laboratory billing practices.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what 0616U represents clinically and operationally, information on typical sites of service, and context for payer engagement. The publication summarizes available benchmarks, payer coverage considerations, and policy trends relevant to proprietary molecular diagnostics, and it outlines what to expect in coding and claims submission for this test. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0616UCPTProprietary Laboratory AnalysesMethylation assayAlzheimer's diseaseMCILaboratory testGenomic diagnostics

Billing Code Overview

CPT code 0616U is a Proprietary Laboratory Analyses (PLA) code for the TruD MDS Alzheimer's & MCI test from TruDiagnostic™ Inc. The test evaluates DNA methylation patterns at more than 30,000 sites in whole blood and uses an algorithmic analysis to report a positive or negative dementia-related risk result. This code applies only to that single manufacturer-specific laboratory assay.

Service Type: Laboratory — proprietary methylation-based dementia risk assay

Typical Site of Service: Clinical laboratory testing on whole blood specimens, billed by the performing laboratory or the proprietary test manufacturer.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult aged 60–75 who presents to a primary care physician or neurologist with new concerns about cognitive decline, memory loss, or subtle changes in executive function reported by the patient or a family member. The clinician documents a focused cognitive history, performs a cognitive screening (for example, MoCA or MMSE), and completes a neurological exam. After initial assessment and when diagnostic uncertainty remains between normal aging, mild cognitive impairment (MCI), and early dementia, the clinician orders the TruD MDS Alzheimer’s & MCI blood-based test (0616U) to assess dementia-related risk using DNA methylation patterns from whole blood.

The clinical workflow typically includes:

Patient visit with cognitive screening and history.
Order placement for the proprietary laboratory analysis 0616U with appropriate requisition and informed consent for genetic/epigenetic testing.
Blood draw performed in an outpatient clinic, phlebotomy center, or diagnostic lab; sample shipped to the performing laboratory (TruDiagnostic™ Inc.).
Laboratory processes methylation assay, runs algorithmic analysis, and returns a binary risk result (positive/negative) to the ordering provider.
Ordering clinician reviews results in context of clinical exam, imaging, and other labs, and documents interpretation and next steps in the medical record. Typical sites of service are outpatient clinics, ambulatory care centers, and commercial laboratory collection sites. The service type is a proprietary laboratory analysis performed by a single manufacturer's laboratory under 0616U.

CPT 0163U: BeScreened–CRC Blood Immunoassay for Colorectal Cancer Risk

CPT-0326U-GUARDANT360-NGS-CFDNA-SOLID-TUMOR-PANEL

CPT 0326U: Guardant360® NGS Cell-Free DNA Solid Tumor Panel

CPT-0155U-PIK3CA-PCR-KIT-THERASCREEN

CPT 0155U: PIK3CA PCR Kit for Breast Tumor Mutation Detection

CPT-0181U-COLTON-CO-BLOOD-GROUP-SEQUENCING

CPT 0181U: Navigator CO Sequencing for Colton Blood Group Antigens

CPT-0342U-IMRRAY-PANCAN-D-PROPRIETARY-PANCREATIC-CANCER-BIOMARKER-ASSAY

CPT 0342U: IMMray PanCan–d Serum Biomarker Assay for Pancreatic Cancer

CPT-0242U-GUARDANT360-CDX-NGS-CTDNA-TUMOR-PROFILING

CPT 0242U: Guardant360 CDx NGS ctDNA Tumor Profiling

CPT-0605U-TRYPTASE-GENE-COPY-NUMBER-ANALYSIS-DPCR

CPT 0605U: Tryptase Gene Copy Number Analysis by dPCR

CPT-0247U-PRETRM-SERUM-BIOMARKER-RISK-FOR-SPONTANEOUS-PRETERM-BIRTH

CPT 0247U: PreTRM® Maternal Serum Biomarker Risk Score for Spontaneous Preterm Birth

CPT-0419U-TEMPUS-NP-PHARMACOGENOMIC-PSYCHOTROPIC-MEDICATION-GUIDANCE

CPT 0419U: Tempus nP Pharmacogenomic Test for Psychotropic Medication Guidance

CPT-0094U-RAPID-WHOLE-GENOME-SEQUENCING-NEWBORNS-INFANTS

CPT 0094U: Rapid Whole Genome Sequencing for Newborns and Infants

Showing 1–10 of 536

Coding Specifications

Modifier	Description	When to Use
`26`	Professional Component	Use when billing only the professional component if the performing lab separates professional and technical components (rare for PLA tests).

TC | Technical Component | Use when billing only the technical component if separated by the performing laboratory.

59 | Distinct Procedural Service | Use when 0616U is billed on the same day as an unrelated laboratory or diagnostic service to indicate a distinct test.

91 | Repeat Clinical Diagnostic Laboratory Test | Use when the test is repeated on the same day for confirmation or assay reliability per lab guidance.

52 | Reduced Services | Use when the test is partially performed and the service is reduced or incomplete per payer rules.

22 | Increased Procedural Services | Use when extraordinary work or interpretation beyond the usual is documented and allowed by the payer.

GQ | Telehealth Origination (DMEPOS) — (Note: CMS legacy) | Rarely used; include only if specific telehealth technical guidance applies to specimen collection oversight.

QW | CLIA Waived Test | Not typical for 0616U; use only if payer/advisory indicates waiver — generally not applicable.

26F | Non-covered (for some payers) | Use per payer instruction when reporting professional component that is non-covered; follow payer-specific guidance.

EX | Separate Encounter (facility dependent) | Use when required by specific commercial payer rules to indicate a separate encounter for laboratory collection or interpretation.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Neurology	Neurologists commonly order dementia risk and cognitive diagnostic testing.

208000000X | Family Medicine | Primary care physicians frequently initiate cognitive evaluation and order diagnostic labs.

207P00000X | Psychiatry | Geriatric psychiatrists evaluate cognitive and behavioral symptoms and may order this test.

363L00000X | Clinical Laboratory | The performing laboratory / lab directors are responsible for test processing and reporting.

207L00000X | Geriatric Medicine | Geriatricians manage older adults with suspected MCI or early dementia and order specialized testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G31.84`	Mild cognitive impairment, so stated	Primary indication for testing to assess risk of progression to dementia.

G30.9 | Alzheimers disease, unspecified | Used when clinician suspects Alzheimer disease as part of the differential diagnosis; test provides adjunctive biomarker risk assessment.

R41.3 | Other amnesia | Relevant for cognitive complaints where memory impairment prompts further diagnostic evaluation including biomarker testing.

R41.82 | Altered mental status, unspecified | Used when patients present with acute or subacute changes in cognition that warrant diagnostic workup.

F02.80 | Dementia in other diseases classified elsewhere without behavioral disturbance | Used when dementia is present or suspected and clinicians seek additional risk stratification.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0616U`	TruD MDS Alzheimer’s & MCI (Proprietary Laboratory Analyses) — DNA methylation analysis of >30,000 sites in whole blood with algorithmic risk output.	This is the primary PLA test performed by TruDiagnostic™ Inc.; report for the specific proprietary assay.

36415 | Collection of venous blood by venipuncture. | Performed at the time of ordering 0616U to obtain the whole blood specimen for the methylation assay.

80307 | Drug testing: molecular pathology procedures, host genomic testing when applicable — (placeholder example). | May be used when companion molecular testing or additional molecular diagnostics are ordered alongside the PLA, depending on payer policies (use payer-specific guidance).

83516 | Drug/therapeutic drug assay (example biochemical assay). | May be billed for ancillary laboratory analyses that are part of the diagnostic workup but not for the PLA itself.

G0473 | Advanced Diagnostic Imaging (example) | Dementia evaluation may include imaging like MRI or PET; this code represents related advanced diagnostic services in the broader workflow.

OpenPayer